Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for atopic dermatitis, asthma, and more. It works to treat those conditions by blocking proteins that cause ...

Dupixent (dupilumab) is a prescription drug that works to treat certain inflammatory conditions, such as atopic dermatitis, by reducing inflammation signals in your immune system. Your response to ...

Both Nucala and Dupixent are used to treat eosinophilic asthma and CRwNP. The two drugs work in different ways to reduce inflammation related to these conditions. Some reports suggest that using ...

Five times more adults on Dupixent achieved sustained disease remission ... this primarily elderly patient population because they work by suppressing their immune system,” said Victoria Werth ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset ...

Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held ...

Dupixent's sales will continue on their upward trajectory for a while; they should succeed in recouping some of Regeneron's Eylea-related losses. A promising gene therapy in the works Another ...

current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 inflammation, which ...

driven by both Eylea and a newer drug called Dupixent. The latter was approved by the FDA in 2017 for the treatment of eczema, but has since been found to work against – and been approved to ...